Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com.

Download and print resources that may help you and your patients in the management of appropriate SBS-IF adult and child patients with Revestive▼(teduglutide). Some materials are also available to order.

Starting on Revestive - Paediatric

This brochure provides information for patients and their caregivers on what to expect from treatment with Revestive and provides relevant information on how they can take an active role in this. 

Download PDF

Starting on Revestive - Adult

This brochure provides information on what to expect from treatment with Revestive, and provides tips on how your patient can take a more active role in their treatment.

Download PDF

Revestive Paediatric Patient Diary

This diary will help the caregiver and their child get the most from treatment with Revestive.

Download PDF

Revestive Adult Patient Diary

This diary will help your patients get the most from their experience with Revestive treatment.

Download PDF

Revestive Leave piece - Paediatric patients

This leave piece summarises key efficacy and safety data for Revestive's use in children

Download PDF

Revestive Leave piece - Adult patients

This leave piece summarises key efficacy and safety data for Revestive's use in adults

Download PDF

Revestive Practical Guide (paediatric patients)

A practical guide to support you with identifying, treating and monitoring paediatric patients

Download PDF

Revestive Practical Guide (adult patients)

A practical guide to support you with identifying, treating and monitoring adult patients

Download PDF

IBD Empower Module 8: Managing intestinal failure in adults

This educational module is part of a series of educational resources from the IBD Empower programme which supports healthcare professionals working in intestinal failure and inflammatory bowel disease (IBD) enabling them to support their patients more effectively.

To request access to this module, contact us on: ibd.empower@takeda.com

C-APROM/GB/REV/0304 Date of preparation April 2025